Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
Suzanne M. Scheaffer, Diana Lee, Bradley Whitener, et al.
Nature Medicine (2022) Vol. 29, Iss. 1, pp. 247-257
Open Access | Times Cited: 150
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 43
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 56
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
Linda Petrone, Alessandro Sette, Rory D. de Vries, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 862-862
Open Access | Times Cited: 25
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, et al.
EBioMedicine (2022) Vol. 87, pp. 104386-104386
Open Access | Times Cited: 27
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 6
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Immunogenicity and Safety of Bivalent Recombinant Protein COVID-19 Vaccine ZF2202: A Randomized, Open-label, Positive-controlled Trial
Huaiyu Yang, Ping Wang, Qiang Wu, et al.
Heliyon (2025), pp. e43100-e43100
Open Access
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
Suzanne M. Scheaffer, Diana Lee, Bradley Whitener, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 26
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
Science Advances (2023) Vol. 9, Iss. 23
Open Access | Times Cited: 12
Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
Abdul Aziz Al-Fattah Bin Yahaya, Kanwal Khalid, Hui Xuan Lim, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 624-624
Open Access | Times Cited: 10
Promising Cytokine Adjuvants for Enhancing Tuberculosis Vaccine Immunity
Xuezhi Cao, Yang–Xin Fu, Peng Hua
Vaccines (2024) Vol. 12, Iss. 5, pp. 477-477
Open Access | Times Cited: 3
Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants
Ziteng Liang, Jincheng Tong, Ziqi Sun, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Closed Access | Times Cited: 2
Comparative analysis of COVID-19 and influenza prevalence among Egyptian pilgrims returning from Hajj and Umrah in 2022: epidemiology, clinical characteristics, and genomic sequencing
Amr Kandeel, Manal Fahim, Ola Deghedy, et al.
Archives of Public Health (2024) Vol. 82, Iss. 1
Open Access | Times Cited: 2
Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread
Himanshu Ajmera, Sudarshan Singh Lakhawat, Naveen Malik, et al.
Current Protein and Peptide Science (2024) Vol. 25, Iss. 4, pp. 307-325
Closed Access | Times Cited: 2
An overview of protein-based SARS-CoV-2 vaccines
Yogesh R. Suryawanshi
Vaccine (2023) Vol. 41, Iss. 42, pp. 6174-6193
Closed Access | Times Cited: 6
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Xiaolan Yong, Jun Liu, Ying Zeng, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 3
Open Access | Times Cited: 6
The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages
Qiaren He, Shiyu Sun, Xi Chen, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 146-146
Open Access | Times Cited: 10
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Alexandre E. Nowill, Manuel Caruso, Pedro O. de Campos‐Lima
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Antibody response to different COVID-19 vaccine regimes: a review
Tamires Cardoso Matsui, Amanda Campelo Lima de Melo, Maria da Conceição Rodrigues Fernandes, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 1, pp. 488-506
Open Access | Times Cited: 1
Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved Immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Xiaolan Yong, Jun Liu, Ying Zeng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top